Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6201 in plaque-type psoriasis
NCT00539929Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of e6201 in plaque psoriasis (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Total Symptom Severity at 8 weeks. Started Sep 2007; status: completed.
02
Drugs
e6201
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00539929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00539929.